Pre-Conference Workshops

Workshop A

Computational Modeling to Aid Target Discovery

Tuesday, April 20 | 10.30-12.00

The use of ‘omics’ data sets with machine learning technologies have proven a powerful combination in understanding disease and revealing ‘hidden’ biology. In this workshop, Oppilotech will demonstrate how it uses ‘big data’ to develop a large scale metabolic model of Escherichia coli. We will look at how our methods have the potential to reveal new biological mechanisms in addition to exploring where model predictions were completely wrong. We will also look at experimental methods aimed at validating or disputing model predictions, and what this means for the use of such models in successfully selecting useful antibacterial targets.

Key Topics to be Covered:

• What are the advantages of using large scale metabolic models over traditional methods?
• What are the limitations in generating computational models?
• Experimental data sets: friends or foe?
• Model inaccuracies, are they failures, or chance to understand?
• How close are we to building complex models for any bacterial cell?

Workshop Leaders

John George

John George
Co-Founder & Chief Scientific Officer
Oppilotech

Ed Siegwart

Ed Siegwart
Director of Microbiology
Oppilotech

Workshop B

Live Bacterial Consortia, a Novel Microbiome- Based Approach for Infection Prevention

Tuesday, April 20 | 13.00-14.30

In the near future, doctors could prescribe drugs made of live bacterial consortia. These drugs have the potential of colonizing the human intestine naturally and repairing microbiome alterations that drive disease. Unlike in faecal transplants, which require the use of donors and are an untargeted, inherently variable procedure, bacterial consortia therapeutics are defined drug compositions produced from clonally isolated bacteria that can trigger targeted immune responses. And in contrast to more reductionistic approaches such as single strain probiotics, they can robustly shift the gut ecosystem. In this workshop, we will discuss live bacterial consortia, which is a novel microbiome- based strategy for infection prevention, as well as discuss Vedanta Bioscience’s approach using insights from microbial ecology, mucosal immunology, and human interventional studies.

Workshop Leader

silvia re size

Silvia Caballero
Associate Director of Infectious Diseases
Vedanta Biosciences

14:30 End of Workshop Day